

Taavi Lehto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5808552/publications.pdf>

Version: 2024-02-01

33
papers

2,199
citations

361045

20
h-index

414034

32
g-index

33
all docs

33
docs citations

33
times ranked

2651
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides. <i>Communications Biology</i> , 2022, 5, 185.	2.0	7
2	Delivery of oligonucleotide-based therapeutics: challenges and opportunities. <i>EMBO Molecular Medicine</i> , 2021, 13, e13243.	3.3	181
3	Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP. <i>Pharmaceutics</i> , 2021, 13, 878.	2.0	24
4	Novel Orthogonally Hydrocarbon-Modified Cell-Penetrating Peptide Nanoparticles Mediate Efficient Delivery of Splice-Switching Antisense Oligonucleotides In Vitro and In Vivo. <i>Biomedicines</i> , 2021, 9, 1046.	1.4	6
5	Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles. <i>ACS Nano</i> , 2021, 15, 13993-14021.	7.3	74
6	Fine Tuning of Phosphorothioate Inclusion in 2'-O-Methyl Oligonucleotides Contributes to Specific Cell Targeting for Splice-Switching Modulation. <i>Frontiers in Physiology</i> , 2021, 12, 689179.	1.3	0
7	Smad-binding decoy reduces extracellular matrix expression in human hypertrophic scar fibroblasts. <i>Molecular Medicine Reports</i> , 2020, 22, 4589-4600.	1.1	3
8	Supramolecular Assembly of Aminoethylene-Lipopeptide PMO Conjugates into RNA Splice-Switching Nanomicelles. <i>Advanced Functional Materials</i> , 2019, 29, 1906432.	7.8	14
9	Sugar and Polymer Excipients Enhance Uptake and Splice-Switching Activity of Peptide-Dendrimer/Lipid/Oligonucleotide Formulations. <i>Pharmaceutics</i> , 2019, 11, 666.	2.0	10
10	Delivery is key: lessons learnt from developing splice-switching antisense therapies. <i>EMBO Molecular Medicine</i> , 2017, 9, 545-557.	3.3	119
11	Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for <i>In Vivo</i> Gene Silencing in Leukemia. <i>Bioconjugate Chemistry</i> , 2017, 28, 2393-2409.	1.8	42
12	Peptides for nucleic acid delivery. <i>Advanced Drug Delivery Reviews</i> , 2016, 106, 172-182.	6.6	174
13	Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand. <i>Biomaterials</i> , 2016, 77, 98-110.	5.7	57
14	Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides. <i>Nano Letters</i> , 2015, 15, 4364-4373.	4.5	80
15	Sequence-Defined Oligoaminoamides for the Delivery of siRNAs. <i>Methods in Molecular Biology</i> , 2015, 1206, 15-27.	0.4	11
16	Sequence-defined polymers for the delivery of oligonucleotides. <i>Nanomedicine</i> , 2014, 9, 2843-2859.	1.7	16
17	Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. <i>Nucleic Acids Research</i> , 2014, 42, 3207-3217.	6.5	82
18	Sensitive and Rapid Detection of <i>Chlamydia trachomatis</i> by Recombinase Polymerase Amplification Directly from Urine Samples. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 127-135.	1.2	120

#	ARTICLE	IF	CITATIONS
19	PepFect14 Peptide Vector for Efficient Gene Delivery in Cell Cultures. <i>Molecular Pharmaceutics</i> , 2013, 10, 199-210.	2.3	83
20	Transfection of Infectious RNA and DNA/RNA Layered Vectors of Semliki Forest Virus by the Cell-Penetrating Peptide Based Reagent PepFect6. <i>PLoS ONE</i> , 2013, 8, e69659.	1.1	7
21	Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. <i>Journal of Controlled Release</i> , 2012, 162, 1-8.	4.8	51
22	The role of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating peptides. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2012, 1818, 502-511.	1.4	80
23	Cell-penetrating peptides for the delivery of nucleic acids. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 823-836.	2.4	125
24	Peptide Nanoparticles for Oligonucleotide Delivery. <i>Progress in Molecular Biology and Translational Science</i> , 2011, 104, 397-426.	0.9	13
25	Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. <i>Nucleic Acids Research</i> , 2011, 39, 3972-3987.	6.5	262
26	Insights into the cellular trafficking of splice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides. <i>Journal of Controlled Release</i> , 2011, 153, 163-172.	4.8	27
27	Novel viral vectors utilizing intron splice-switching to activate genome rescue, expression and replication in targeted cells. <i>Virology Journal</i> , 2011, 8, 243.	1.4	9
28	A Peptide-based Vector for Efficient Gene Transfer In Vitro and In Vivo. <i>Molecular Therapy</i> , 2011, 19, 1457-1467.	3.7	94
29	PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. <i>Nucleic Acids Research</i> , 2011, 39, 5284-5298.	6.5	199
30	Application of PepFect Peptides for the Delivery of Splice-Correcting Oligonucleotides. <i>Methods in Molecular Biology</i> , 2011, 683, 361-373.	0.4	18
31	Delivery of nucleic acids with a stearylated (R _x R) ₄ peptide using a non-covalent co-incubation strategy. <i>Journal of Controlled Release</i> , 2010, 141, 42-51.	4.8	113
32	Cellular Internalization Kinetics of (Luciferin-)Cell-Penetrating Peptide Conjugates. <i>Bioconjugate Chemistry</i> , 2010, 21, 1662-1672.	1.8	42
33	Chemically modified cell-penetrating peptides for the delivery of nucleic acids. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 1195-1205.	2.4	56